Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Research & Development (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Research & Development for 5 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • For Q4 2025, Research & Development fell 68.32% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $33.8 million, down 48.65%, while the annual FY2025 figure was $33.8 million, 48.65% down from the prior year.
  • Research & Development hit $5.1 million in Q4 2025 for Kezar Life Sciences, down from $6.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $23.7 million in Q3 2023 and bottomed at $5.1 million in Q4 2025.
  • Average Research & Development over 5 years is $13.8 million, with a median of $13.0 million recorded in 2022.
  • Year-over-year, Research & Development skyrocketed 85.08% in 2023 and then crashed 68.32% in 2025.
  • Kezar Life Sciences' Research & Development stood at $9.8 million in 2021, then soared by 51.92% to $14.9 million in 2022, then soared by 52.38% to $22.6 million in 2023, then fell by 29.2% to $16.0 million in 2024, then plummeted by 68.32% to $5.1 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $5.1 million, $6.9 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.